Certolizumab pegol in the treatment of psoriasis: Real‐life data. Issue 3 (10th March 2021)

• Record Type: Journal Article
• Authors: Turkmen, Meltem; Dogan, Sinan
• Is Part Of: Dermatologic therapy. Volume 34:Issue 3(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-10
• Subjects: anti‐TNF -- certolizumab pegol -- chronic plaque psoriasis -- COVID‐19; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14929
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Certolizumab pegol (CZP), the only Fc‐free, PEGylated anti‐tumor necrosis factor biologic agent. This study aims to investigate the effect and safety of CZP in moderate‐to‐severe chronic plaque psoriasis. We performed a retrospective observational analysis of the moderate‐to‐severe psoriasis patients under ceratolizumab pegol therapy. Primer endpoints were efficacy of CZP, defined as statistically significant improvement of Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), and clinical Disease Activity index for Psoriatic Arthritis (cDAPSA) in the 24 week of therapy. Secondary endpoints were safety of CZP especially during COVID‐19 pandemic. Fifty‐six moderate‐to‐severe psoriasis patients treated with CZP were evaluated retrospectively. We observed a rapid and significant reduction of PASI, PGA, and cDAPSA scores in W4. After loading dose, we observed loss of clinical efficacy of CZP in eight patients and optimized therapy by increasing the dosing of CZP. Dose escalation of CZP permitted the achievement and long‐term maintenance of clinical improvement in these patients. We compare the clinical efficacy of CZP between naive and patients who has been treated with other biologic agents. There were no statistical differences in efficacy between these two groups. No side effects were observed during CZP treatment. There were no cases of death from COVID‐related disease in our study population or patients hospitalized for COVID‐19 related disease. Our results demonstrate that CZP is an effective and safe therapeutic option for patients with moderate‐to‐severe chronic plaque psoriasis.